Myriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nat...
October 21 2016 - 9:29AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in
personalized medicine, and ION Solutions, a part of
AmerisourceBergen, and the largest physician services organization
specializing in the support of community oncology, announced today
that they have entered into a relationship to deliver quality
hereditary cancer test results and services to ION member
practices. Through this relationship, Myriad and ION will work
together to enhance the operational and clinical value associated
with hereditary cancer testing. Myriad will be ION’s
preferred partner for hereditary cancer testing focused on bringing
specialized tests and services to meet the specific needs of
community oncology practices. This partnership will advance the
organizations’ shared goals of providing accurate and comprehensive
hereditary cancer test results and service to community oncologists
and their patients.
“Myriad has demonstrated its commitment to
quality with its significant investments in research, laboratory
processes, variant interpretation and exceptional customer
service,” said Mark Santos, RPh, president of ION GPO. “This
relationship supports ION Solutions in making important genetic
tests available to our members in a way that will help inform
treatment decisions and build patient care plans in the
context of specific practice processes and objectives.”
"ION Solutions is the industry leader in
bringing effective business and clinical solutions to the largest
segment of community oncology practices in the nation,” said
Alexander Ford, president of Myriad Genetic Laboratories, Inc. "Our
focus as a company is on providing accurate, affordable and
clinically significant genetic test results to providers and the
patients they care for. We believe we share this commitment with
ION Solutions and their members, and that through this partnership,
the largest, most innovative private practices in the country will
gain enhanced access to our services.”
About ION Solutions and AmerisourceBergenION
Solutions, a part of AmerisourceBergen Corporation, is the largest
physician service organization and GPO specializing in the support
of community oncology. ION provides GPO procurement services,
technologies, advocacy resources and expertise to more than half of
the community-based oncology practices in the nation to help
improve their clinical and operational management. Additional
information can be found at www.iononline.com.
AmerisourceBergen is one of the largest global pharmaceutical
sourcing and distribution services companies, helping both
healthcare providers and pharmaceutical and biotech manufacturers
improve patient access to products and enhance patient care. With
services ranging from drug distribution and niche premium logistics
to reimbursement and pharmaceutical consulting
services, AmerisourceBergen delivers innovative programs
and solutions across the pharmaceutical supply channel in human and
animal health. With over $140 billion in annual
revenue, AmerisourceBergen is headquartered
in Valley Forge, PA, and employs approximately 19,000
people. AmerisourceBergen is ranked #12 on the Fortune
500 list. For more information, go
to www.amerisourcebergen.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, Vectra, GeneSight and Prolaris are trademarks or
registered trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G.
Safe Harbor StatementThis press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements relating to Myriad being ION’s preferred partner for
hereditary cancer testing; and the Company’s strategic directives
under the caption “About Myriad Genetics.” These “forward-looking
statements” are based on management’s current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those described or implied in the
forward-looking statements. These risks include, but are not
limited to: the risk that sales and profit margins of our existing
molecular diagnostic tests and pharmaceutical and clinical services
may decline or will not continue to increase at historical rates;
risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of a
healthcare clinic in Germany; risks related to our projections
about the potential market opportunity for our products; the risk
that we or our licensors may be unable to protect or that third
parties will infringe the proprietary technologies underlying our
tests; the risk of patent-infringement claims or challenges to the
validity of our patents; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; and other factors discussed under the heading
“Risk Factors” contained in Item 1A of our Annual Report on Form
10-K for the fiscal year ended June 30, 2016, which has been filed
with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024